

# John Paul Rocchiccioli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7827183/publications.pdf>

Version: 2024-02-01

30  
papers

4,313  
citations

777949

13  
h-index

620720

26  
g-index

30  
all docs

30  
docs citations

30  
times ranked

5572  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. <i>Cardiovascular Research</i> , 2022, 118, 1535-1547.	1.8	6
2	Shockwave Coronary Intravascular Lithotripsy System for Heavily Calcified De Novo Lesions and the Need for a Cost-Effectiveness Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2022, 37, 128-134.	0.3	9
3	Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial. <i>EuroIntervention</i> , 2022, 17, 1467-1476.	1.4	8
4	Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR). <i>European Heart Journal</i> , 2021, 42, 4656-4668.	1.0	79
5	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. <i>Open Heart</i> , 2021, 8, .	0.9	1
6	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. <i>Open Heart</i> , 2021, 8, e001453.	0.9	2
7	Sex differences in procedural and clinical outcomes following rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 232-241.	0.7	24
8	1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 33-45.	1.1	141
9	Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2817-2829.	1.2	40
10	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. <i>European Heart Journal</i> , 2020, 41, 3239-3252.	1.0	73
11	Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e014066.	1.6	11
12	Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. <i>Heart</i> , 2020, 106, 758-764.	1.2	13
13	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-86.	0.9	0
14	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007830.	1.4	17
15	50% Ischaemia and No Obstructive Coronary Artery Disease (INOCA): prevalence and predictors of coronary vasomotion disorders. , 2019, , .		0
16	Post-operative myocardial infarction following aortic root surgery with coronary reimplantation: a case series treated with percutaneous coronary intervention. <i>European Heart Journal - Case Reports</i> , 2019, 3, 1-6.	0.3	4
17	Ischemia and No Obstructive Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008126.	1.4	107
18	Type 1 diabetes mellitus and coronary revascularization. <i>Cardiovascular Endocrinology and Metabolism</i> , 2019, 8, 35-38.	0.5	4

#	ARTICLE	IF	CITATIONS
19	MINOCA: Requirement for Definitive Diagnostic Work-Up. <i>Heart Lung and Circulation</i> , 2019, 28, e4-e6.	0.2	3
20	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. <i>American Heart Journal</i> , 2018, 201, 86-94.	1.2	22
21	Coronary angiography in heart failure: when and why? Uncertainty reigns. <i>Heart</i> , 2018, 104, 548-549.	1.2	2
22	Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. <i>Open Heart</i> , 2018, 5, e000924.	0.9	12
23	Systemic microvascular dysfunction in microvascular and vasospastic angina. <i>European Heart Journal</i> , 2018, 39, 4086-4097.	1.0	139
24	Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2841-2855.	1.2	436
25	9â€¦Routine non-invasive vs invasive management in patients with prior CABG with a NSTEMI-ACS: a randomised controlled trial. , 2018, , .		0
26	A keen eye for risk. <i>BMJ: British Medical Journal</i> , 2018, 360, j5884.	2.4	0
27	Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 317-326.	1.9	91
28	Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	67
29	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). <i>Open Heart</i> , 2016, 3, e000371.	0.9	7
30	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2999-3054.	1.0	2,995